drugset / Trial / NCT03277209
To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas
Phase 1
Terminated
2 enrolled
Weill Medical College of Cornell University
Cambridge University Hospitals NHS Foundation Trust · collab
NaSingle-groupOpen-labelTreatment
Summary
A dose escalation trial to assess the safety of plerixafor in patients with advanced pancreatic, high grade serous ovarian and colorectal cancer. To identify the proof of mechanism, by demonstrating alterations in T-cell tumour distribution, ideally associated with loss of tumour cells, measured by immunostaining, and changes in FDG uptake.
Timeline
- Start
- 2017-07-25
- Primary completion
- 2019-12-30
- Completion
- 2019-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Plerixafor | Small molecule | 20 ug/kg | Intravenous |
| Subject | Plerixafor | Small molecule | 40 ug/kg | Intravenous |
| Subject | Plerixafor | Small molecule | 80 ug/kg | Intravenous |
| Subject | Plerixafor | Small molecule | 120 ug/kg | Intravenous |